However, primary care has not always been able to deliver such a role; up to the end of the 1980s, despite the drawbacks of busy hospital outpatient clinics,

primary care could rarely offer the systematic care and skills that people with diabetes require. Quality improvement and audit in the 1990s heralded the increased adoption of evidence-based practice in primary care. Many GP practices significantly improved the organisation and quality of care for diabetes as a result. The widespread adoption of IT systems and the emergence of a more robust evidence base for care (for example, UKPDS) accelerated this process. More lately, investment in general practice through the Quality and Outcomes Framework and Selleck PS341 practice education programmes have helped deliver significant improvements in the quality of primary care diabetes. However, there is still much to do, with variation in care and health inequalities persisting. The development of clinical commissioning offers further opportunities to make the best use of available resources and target investment where it is most likely to benefit patients. A health care system where primary care in collaboration with other stakeholders coordinates

http://www.selleckchem.com/products/MK-1775.html the care of people with diabetes offers the best hope in addressing this modern epidemic that we face. Copyright © 2012 John Wiley & Sons. This paper was presented as the 2012 Mary Mackinnon lecture at the 2012 Diabetes UK Annual Professional Conference held in Glasgow “
“Clinical symptoms of diabetes-related complications are very rare in children and adolescents with type 1 diabetes (T1D). Screening for complications aims to detect their presence

shortly after development but before they cause clinically significant symptoms. Early detection of complications, alongside efforts to improve glycaemic control, can slow the progression of microvascular complications with consequently improved quality of life and life expectancy. An ideal screening programme should be evidence based and should include the majority of clinically important complications and associated diseases. O-methylated flavonoid Such programmes have been formulated by multidisciplinary bodies representing a number of specialist diabetes societies worldwide. The purpose of this review is to highlight the importance of screening for diabetes complications and comorbidities in T1D in childhood and to review and compare the latest guidelines of the International Society for Pediatric and Adolescent Diabetes, American Diabetes Association, Canadian Diabetes Association, Australian Government National Health and Medical Research Council, and the UK National Institute for Health and Clinical Excellence. Copyright © 2011 John Wiley & Sons.